Research Summary: For patients with bacillus Calmette-Guérin (BCG)–naïve, high-risk non-muscle invasive bladder cancer (NMIBC), the standard of care is transurethral resection of bladder tumor (TURBT) followed by BCG therapy. However, early recurrence rates remain high, and patients with early recurrence and high-risk NMIBC face an...
Read MoreResearch Summary: Many estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) breast tumors develop resistance to aromatase inhibitors (AIs) alone or in combination with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. However, the capacity for selective ER degraders (SERDs) to induce ER alpha degradation...
Read MoreResearch Summary: Muscle invasive bladder cancer (MIBC) is an aggressive subtype of bladder cancer that invades the musculature of the bladder wall. Current standard treatment involves neoadjuvant chemotherapy followed by radical cystectomy, but MIBC carries a high risk of recurrence, with about half of patients...
Read MoreResearch Summary: Unresectable, stage III non-small cell lung cancer (NSCLC) is treated with concurrent chemoradiotherapy (cCRT) followed by durvalumab for up to 12 months, which improves progression-free survival (PFS) and overall survival (OS) compared to cCRT alone. However, many patients receive sequential chemoradiotherapy (sCRT) rather...
Read MoreResearch Summary: KRAS G12C mutations occur in a substantial subset of advanced non-small cell lung cancer (NSCLC), and current first-line standards based on immune checkpoint inhibitors (ICIs), with or without chemotherapy, yield suboptimal long-term outcomes. Olomorasib is an orally bioavailable, highly selective KRAS G12C inhibitor...
Read MoreResearch Summary: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are B-cell malignancies that frequently affect older adults and often require prolonged use of Bruton tyrosine kinase inhibitor (BTKi) therapy in the relapsed or refractory (R/R) setting. Ibrutinib and acalabrutinib are both recommended BTKis...
Read MoreResearch Summary: Capivasertib is a potent, selective inhibitor of all three protein kinase B (AKT1/2/3) isoforms. The phosphoinositide 3- kinase/protein kinase B pathway is frequently overactivated in many solid tumors, including hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) breast cancer. In the...
Read MoreResearch Summary: Covalent Bruton tyrosine kinase (BTK) inhibitors have become the preferred treatment for chronic lymphocytic leukemia (CLL). However, the first-generation BTK inhibitor ibrutinib, though effective, has been associated with cardiac toxicity, including atrial fibrillation, heart failure, and sudden death. Acalabrutinib, a second-generation, more selective...
Read More
Dr. Gautam Jayram highlights how adding durvalumab to standard gemcitabine–cisplatin...
Read More
Dr. Haley Ellis discusses efficacy data from the TOPAZ-1 clinical...
Read More
Stephanie Gregory, MS, FNP-C, BMTCN, and Jacob Bartlett, PA-C, from...
Read More
Dr. Midhun Malla discusses the evolving treatment landscape for advanced...
Read More
Petros Grivas, MD, PhD, of the University of Washington and...
Read More
Hagen Kennecke, a medical oncologist and professor of medicine at...
Read More
Kevin Brigle, PhD, ANP, explains the importance of improving proper...
Read More
Romanos Sklavenitis-Pistofidis, MD, discusses that now that patients with smoldering...
Read More
Nilo Azad, MD, a medical oncologist at Johns Hopkins, highlighted...
Read More
Monica White, RN, discusses her session focusing on the bone...
Read More
Francesco Corrado elaborated on the results of his research, noting...
Read More
Lisa Hwa Christenson, APRN, DNP, CNP, FAPO, and Miriam Hobbs,...
Read More©2026 Oncology Matrix. All Rights Reserved.
